Opportunity for RGNX Investors to Lead Class Action Against REGENXBIO Inc. Alleging Securities Fraud

Investors Encouraged to Participate in Class Action

The Schall Law Firm, known for its commitment to shareholder rights, has issued an invitation to investors impacted by alleged securities fraud involving REGENXBIO Inc. This action highlights potential violations of securities laws which could impact numerous shareholders.

Background of the Case

From February 9, 2022, to January 27, 2026, REGENXBIO Inc. (NASDAQ: RGNX) has come under scrutiny for its public statements surrounding the product candidate RGX-111. Allegations suggest that the company misled the market regarding the efficacy and safety of this drug, impacting investors' financial decisions significantly.

According to the complaint, RGX-111 was touted as a breakthrough treatment, despite undisclosed negative data regarding its safety. The lawsuit specifically calls out a significant incident where an intra-cerebral tumor was identified in a participant during clinical trials, an event that sharply contradicted the company's previously optimistic forecasts.

This discrepancy led to an immediate downturn in the company's stock value once the information was disclosed, resulting in significant financial losses for investors who relied on earlier statements from the company.

Who Can Participate?

The Schall Law Firm is urging all investors who purchased REGENXBIO securities during the stated class period to reach out before April 14, 2026. Those who endured financial losses may be eligible to recover some of their damages through this class-action lawsuit.

The importance of taking action in such situations cannot be overstated. If you feel your investment has been impacted by possibly fraudulent claims, joining this class action could be a vital step in asserting your rights as a shareholder.

How to Get Involved

Interested parties can contact Brian Schall directly at the Schall Law Firm for further guidance. Discussions regarding your rights are free of charge, and all inquiries can also be made through the firm's official website or via email.

Legal Representation and Class Certification

It’s crucial to note that the class has not yet been certified. Until this certification is granted, individuals who choose to remain passive may be classified as absent members. Therefore, timely action is advisable to ensure participation in this lawsuit.

The Schall Law Firm reiterates its commitment to represent investors across the world. Specializing in securities class action lawsuits, they aim to foster accountability and transparency in the capital markets.

Conclusion

In investing, awareness and action are transformative. By joining this lawsuit, investors may have the opportunity to recoup losses incurred due to potentially misleading practices by REGENXBIO. With the firm’s expertise at your disposal, now is the moment to assess your position and act accordingly.

For more information, reach out to the Schall Law Firm today and explore the options available to recover your losses due to this legal situation.